Adjunctive use of an artificial intelligence (AI) software demonstrated nearly equivalent sensitivity and over 28 percent higher accuracy in comparison to radiologist assessment of breast ultrasound images for breast lesions, according to new research presented at the recent Society of Breast Imaging (SBI) conference.
In new research comparing the use of adjunctive artificial intelligence (AI) to radiologist assessment of breast ultrasound images, researchers found that adjunctive AI had over a 28 percent higher accuracy rate and a nearly 40 percent higher specificity rate for diagnosing breast lesions.
For the retrospective study, presented at the recent Society of Breast Imaging (SBI) conference, researchers assessed the adjunctive use of Koios Decision Support (DS) Breast (Koios Medical) in interpreting breast ultrasound for the diagnosis of breast lesions. The study involved 154 biopsy-proven cases (mean age of 53.2) from a diverse patient population comprised of 33.1 percent White patients, 29.9 percent Hispanic patients, 15.6 percent Black/African American patients, 14 percent Asian patients and 12.3 percent multi-racial patients, according to the study.
The researchers found that use of the Koios DS Breast software had a 60.4 accuracy rate in comparison to a 31.8 percent accuracy rate for radiologist assessment of breast lesions on ultrasound as well as a 97.5 sensitivity rate. There was also a significant reduction of false positives with the AI software (60) in comparison to 105 false positive diagnoses for radiologist assessment without AI.
Images courtesy of the Society of Breast Imaging (SBI).
“Our preliminary results show there is promise that an AI (decision support) system would be an accurate and reliable second opinion in diagnostic ultrasound examinations,” noted lead study author Clara Koo, M.D., a diagnostic radiology resident affiliated with the Mount Sinai Health System in New York, N.Y., and colleagues. “Furthermore, (the AI software) has the potential to reduce false positive readings, especially in younger patients, reducing the burden of unnecessary biopsies.”
In the diverse patient cohort, the researchers also noted no evidence of racial- or machine-based bias affecting the study results. Koo and colleagues added that there was increasing correlation between the AI software and radiologist assessment with advancing patient age.
(Editor’s note: For related content, see “Automated Breast Ultrasound: Is it a Viable Second-Look Option for Women with Dense Breasts?” and “Can Multimodal AI Improve Cancer Detection in Dense Breasts?”)
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.